Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : BL-001
Therapeutic Area : Nutrition and Weight Loss
Study Phase : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Bloom Science's BL-001 Shows Significant Weight Loss in Phase 1 Trial
Details : BL-001 is an investigational oral therapy designed to replicate the positive effects of the ketogenic diet, being investigated in adults ranging from healthy weight to overweight.
Product Name : BL-001
Product Type : Probiotic
Upfront Cash : Inapplicable
March 04, 2025
Lead Product(s) : BL-001
Therapeutic Area : Nutrition and Weight Loss
Highest Development Status : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : BL-001 is a first-in-class, orally delivered, live biotherapeutic product being developed by Bloom Science for the treatment of multiple neurological diseases, including Dravet syndrome and ALS.
Product Name : BL-001
Product Type : Probiotic
Upfront Cash : Inapplicable
August 17, 2023
Details : BL-001 is a live biotherapeutic product, designed to modulate GABA and other key bioenergetic pathways to suppress hyperexcitability which is a key driver in seizures associated with dravet syndrome and other rare developmental and epileptic encephalopat...
Product Name : BL-001
Product Type : Probiotic
Upfront Cash : Inapplicable
April 25, 2023
Lead Product(s) : BL-001
Therapeutic Area : Neurology
Study Phase : Preclinical
Sponsor : Leaps by Bayer
Deal Size : $12.0 million
Deal Type : Series A Financing
Bloom Science Raises USD $12 Million in Series A Financing
Details : The investment will enable Bloom to file an Investigational New Drug (IND) application for BL-001 in refractory epilepsy and advance into Phase I clinical trials, as well as further expand development of its platform and advance its research and talent a...
Product Name : BL-001
Product Type : Probiotic
Upfront Cash : Undisclosed
September 12, 2021
Lead Product(s) : BL-001
Therapeutic Area : Neurology
Highest Development Status : Preclinical
Sponsor : Leaps by Bayer
Deal Size : $12.0 million
Deal Type : Series A Financing
Lead Product(s) : BL-001
Therapeutic Area : Neurology
Study Phase : Preclinical
Sponsor : ALS Association
Deal Size : $0.5 million
Deal Type : Funding
The ALS Association Awards Bloom Science for Novel Microbiota-based Therapies
Details : Bloom is leveraging its GOLD platform in combination with strong pre-clinical data to advance a new generation of therapeutics aimed at managing gut microbiota.
Product Name : BL-001
Product Type : Probiotic
Upfront Cash : Undisclosed
March 17, 2020
Lead Product(s) : BL-001
Therapeutic Area : Neurology
Highest Development Status : Preclinical
Sponsor : ALS Association
Deal Size : $0.5 million
Deal Type : Funding